RBDCOV PROJECT | PODCAST SERIES

‘RBDCOV Talks' brings vaccine clinical research closer to the general audience through a podcast series with 10 scientists, clinicians, specialists and community advocates who are partners in the project.

‘RBDCOV Talks' brings vaccine clinical research closer to the general audience through a podcast series with 10 scientists, clinicians, specialists and community advocates who are partners in the project.
November 29, 2023

With almost two years under its belt, the RBDCOV project, dedicated to the development of HIPRA’s BIMERVAX® vaccine against COVID-19 and financed by the European Union under the Horizon Europe programme, explores new dissemination channels through the production of its own podcast: ‘RBDCOV Talks’.

This initiative consists of a series of ten podcast episodes with the participation of clinical research teams, medicine professionals and community advocates in order to facilitate access to technical knowledge for non-specialist groups. At the same time, RBDCOV Talks’ informs the community about the current progress and results of ongoing clinical trials testing the efficacy, tolerability and safety of HIPRA’s recombinant BIMERVAX® vaccine.

Do not miss Asphalion’s expert Helena Belinchón on episode 2 “What’s Drug Safety? What is Drug Safety-level monitoring like in vaccine clinical trials?” and discover the critical role of Drug Safety in vaccine clinical trials.

The complete ‘RBDCOV Talks’ series is available in English from today on three major podcast distribution platforms – Spotify, Ivoox and Apple Podcasts.

You can contact us for further information at: [email protected]

 

Search News & Events

  • Filter by category

Share

Related news and events

HORIZON EUROPE | NABIHEAL progress meeting

Two years into the NABIHEAL project, Asphalion experts Marta Rayo Lunar and Sergio Veiga attended the consortium meeting in Zagreb, hosted by IMI, to review

HORIZON EUROPE PROJECT | KeratOPrinter Kick-Off Meeting

Corneal blindness affects over 11.7 million people worldwide, yet only 1 in 70 patients receive a corneal transplant due to a severe donor shortage. The KeratOPrinter project aims to address this gap by developing a groundbreaking 4D bioprinting suite capable of producing fully functional, biocompatible human corneas. Combining expertise from world-class partners, the project focuses on scalable cell sources, advanced bioinks, high-precision bioprinting, clinical handling solutions, regulatory compliance, and a strong collaborative network. By 2035, KeratOPrinter seeks to revolutionize corneal transplantation and restore vision for millions.

ARDAT PROJECT

A new year, new classes, and a deep dive into advanced therapies, including discussions on the ARDAT project, as part of the University of Sheffield’s

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting